Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #666 | July 1, 2016  

Important Patent Issued for Fibrotic Research

ibio-logo.pngiBio, Inc. has announced the issue by the U.S. Patent and Trademark Office on June 14, 2016 of a new patent covering the company's fibrosis therapeutics product pipeline.

The new patent is on an invention by iBio's collaborators, Dr. Carol Feghali-Bostwick and colleagues. It is entitled "USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS" and includes claims covering composition of matter and methods of use for endostatin-related peptides.

iBio obtained exclusive licenses to the prior patents and related intellectual property developed by Dr. Feghali-Bostwick and then entered into an ongoing collaboration agreement with Dr. Feghali-Bostwick's current institution, the Medical University of South Carolina (MUSC), which led to further development and invention of the potentially breakthrough biotherapeutic approach to fibrotic diseases described by this family of patents.

Data published by Dr. Feghali-Bostwick, now the Kitty Trask Holt and SmartState® SC Centers of Economic Excellence Endowed Professor at MUSC and Vice Chair of the Scleroderma Foundation’s National Board of Directors, indicate that the endostatin-derived peptides covered by these patents demonstrated both inhibition and reversal of fibrosis in generally accepted preclinical mouse models of fibrosis as well as in human skin. iBio has produced the active pharmaceutical ingredients for the product candidates covered by these patents using its patented proprietary gene expression technology and expects to manufacture material for human clinical trials, and for large-scale production of any product that receives regulatory approval, in the Bryan, Texas facilities of iBio's new subsidiary, iBio CMO LLC.

Click here for more >>

Have you Registered for our 2016 National Patient Education Conference Yet?

Save the Date, slider imageIf you have not registered for this year's conference in New Orleans, act now!  Our regular registration rate increase after July 7.  That's less than a week!  The 18th annual National Patient Education Conference offers educational and networking opportunities for people living with scleroderma, their caregivers, family members and friends.  We also offer a kids program at the conference that is open to younger patients, their siblings or even the child of an adult patient. Register now and take advantage of the regular registration rates.

Click here to register >>

Growing Market for Smart Gadgets to Improve Sleep

sleep.jpgSleep is essential for good health, yet getting enough of it eludes most Americans. The Centers for Disease Control and Prevention says more than one in three American adults don't get enough sleep. For nearly 83 million of us, it's usually less than seven hours a night. Now there's a growing market for gadgets that promise to track sleep habits to help you get a better night's sleep.

Click here for more >>


The White House Office of Science and Technology Policy (OSTP) Announces New National Microbiome Initiative (NMI)

19JPMICROBIOME1-popup.jpgIn collaboration with federal agencies and private-sector stakeholders, the White House Office of Science and Technology Policy (OSTP) announced a new initative to foster the intergrated study of microbiomes. Microbiomes are the communities of microorganisms that live on or in people, plants, soil, oceans, and the atmosphere. Microbiomes maintain healthy function of these diverse ecosystems, influencing human health, climate change, food security, and other factors. Dysfunctional microbiomes are associated with issues including human chronic diseases

Click here for more >> 

National Office will be Closed on Monday

Please note:  The National Office will be closed Monday, July 4, 2016 in observance of Independence Day.  We will reopen again at 8:30AM EST Tuesday, July 5, for regular business hours.

Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat

Actelion 2016 sponsor
2016 Bayer Logo
2016 Bronze National Sponsor Reata
2016 Gilead Silver Conference Sponsor
United Therapeutics Logo



Sencis Ad - eLetter

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.